Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Expenses: 2016-2024

Historic Operating Expenses for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to $395.6 million.

  • Rhythm Pharmaceuticals' Operating Expenses rose 34.76% to $104.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year decrease of 4.63%. This contributed to the annual value of $395.6 million for FY2024, which is 51.13% up from last year.
  • Rhythm Pharmaceuticals' Operating Expenses amounted to $395.6 million in FY2024, which was up 51.13% from $261.8 million recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Operating Expenses registered a high of $395.6 million during FY2024, and its lowest value of $173.2 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $261.8 million (2023), whereas its average is $286.7 million.
  • Data for Rhythm Pharmaceuticals' Operating Expenses shows a peak YoY skyrocketed of 51.13% (in 2024) over the last 5 years.
  • Over the past 4 years, Rhythm Pharmaceuticals' Operating Expenses (Yearly) stood at $173.2 million in 2021, then climbed by 17.08% to $202.8 million in 2022, then rose by 29.09% to $261.8 million in 2023, then skyrocketed by 51.13% to $395.6 million in 2024.